Humana
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
BISHOP ROBERT BARRON: Pope Leo sees the AI age clearly — and warns we must save our souls
Pope Paul VI’s 1968 encyclical Humanae vitae covers a variety of themes, both theological and anthropological, and has proved to be remarkably prophetic, and yet it is still, in the minds of most people, simply the "birth control" encyclical. Similarly, Pope Francis’s 2015 encyclical Laudato Si’ ranges across a number of topics and provides a trenchant analysis of the philosophy that dominates the modern world, and yet, for most, it is simply the "global warming" encyclical. I am a bit...
New dating of Spain's Sala Keimada rock art sanctuary reveals thousands of years of continuous use
New dating of Spain's Sala Keimada rock art sanctuary reveals thousands of years of continuous use Gaby Clark Scientific Editor Robert Egan Associate Editor The Centro Nacional de Investigación sobre la Evolución Humana (CENIEH) has participated in a study published in the Journal of Archaeological Science: Reports on Sala Keimada, one of the rock art sanctuaries in Cueva Palomera, the main cave of the Ojo Guareña Karst Complex (Merindad de Sotoscueva, Burgos, Spain). Led by Ana Isabel...
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs. Novo Nordisk on Sunday announced that prescriptions of the Wegovy pill have topped 3 million since it entered the U.S. market about five months ago. The Danish drugmaker's CEO Mike Doustdar celebrated the milestone, saying in an interview with CNBC that Novo was able to accelerate prescriptions even as Lilly...
No tech, no problem. Dow makes record and traders think these stocks can lead now
The flashiest group in the market took a step back Thursday as chip stocks dropped 1.5%, but U.S. stock market bulls didn't miss a beat. The Dow Jones Industrial Average closed at a fresh record following a 2% pop and the S&P 500 bounced 0.4% as 9 of 11 sectors advanced. Health-care stocks led gains and options traders followed suit, piling into the group as a handful of insurers and drugmakers pushed toward new highs.